Study guide
Transplantation And Compatibility Concepts
ASCP MLS Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Orientation To ASCP MLS Certification
Credential Purpose And Role ASCP BOC And Eligibility At A High Level MLS Versus MLS(ASCPi) Wording Application Fee And Transcript Result Basics CAT Exam Model Overview Study Plan From Content Guideline
2 Exam Format, CAT Scoring, And Score details
100 Questions And 2h30m Computer Adaptive Testing One-Best-Answer Multiple Choice Theoretical Versus Procedural Questions Scaled Score 100-999, Minimum 400 Score Notification Timing And Transcript Dependency
3 Blood Banking
Products And Components Blood Group Systems And Immunology Serologic And Molecular Testing Compatibility Testing And Transfusion Practice Physiology And Pathophysiology High-Yield Study Strategy
4 Chemistry
Carbohydrates, Lipids, Proteins, And Nitrogen Compounds Enzymes And Heme Derivatives Acid-Base, Blood Gases, And Electrolytes Endocrinology, Vitamins, And Nutrition Therapeutic Drug Monitoring And Toxicology Calculations And Correlation
5 Hematology And Hemostasis
Normal Hematopoiesis And Cell Morphology Anemia And RBC Disorders Leukocyte Disorders And Disease States Platelet And Coagulation Physiology Hemostasis Testing Smear, Analyzer, And Result Correlation
6 Microbiology
Preanalytic Specimen Handling Bacteriology Analytic Procedures Susceptibility And Organism Identification Logic Mycobacteriology, Virology, Parasitology, And Mycology Postanalytic Reporting Safety And Contamination Awareness
7 Urinalysis And Other Body Fluids
Physical And Chemical Urinalysis Microscopic Sediment Renal Physiology And Disease States CSF And Serous Fluids Body Fluid Cell Counts And Crystals Correlation And Preanalytic Issues
8 Immunology
Principles Of Immune Response Immune-System Diseases Infectious Disease Serology Transplantation And Compatibility Concepts Serologic Procedures And Test Methodology Interpretation Pitfalls
9 Laboratory Operations
Quality Assessment And Troubleshooting Safety Laboratory Mathematics Manual And Automated Methodology Instrumentation And Validation Management And Education Principles
10 Integrated Case Reasoning And Calculations
Correlating Patient Results To Disease States Applying Knowledge To New Facts Calculations And Units Procedural Decision-Making QA/QC In Case Questions Avoiding Memorization-Only Study
11 Practice Strategy And Remediation
Content Percentage Allocation CAT-Aware Practice Mindset Reviewing Misses By Domain Using The Official Guideline Before Third-Party Materials Transcript And Result Timing In Planning Final Remediation Cycles
12 Final Review And Exam-Day Readiness
Final-Week Schedule Timing And Pacing Score Expectations Result And Credential Next Steps Digital Badge And Documentation Post-Exam Actions Without Promises
Transplantation And Compatibility Concepts
Key Takeaways Explain This Topic AI
The human leukocyte antigen (HLA) system encoded on chromosome 6 governs transplant compatibility; class I (A, B, C) is on all nucleated cells, class II (DR, DQ, DP) on antigen-presenting cells.
Hyperacute rejection occurs within minutes from preformed recipient antibodies; acute rejection is T-cell-mediated over days to weeks; chronic rejection occurs over months to years.
Graft-versus-host disease (GVHD) occurs when donor T cells attack the recipient, classically an immunocompromised recipient after bone marrow transplant or non-irradiated cellular blood products, or an immunocompetent recipient who shares HLA with the donor, usually a relative.
Crossmatching and HLA typing detect recipient antibodies against donor antigens before transplant to prevent rejection.
Last updated: November 2026
The HLA / MHC System
The human leukocyte antigen (HLA) system is the human major histocompatibility complex (MHC) , encoded on the short arm of chromosome 6 . It is the most polymorphic system in humans and the primary determinant of transplant compatibility. HLA genes are inherited as a haplotype (a linked set from each parent) in a codominant fashion, so each person expresses both maternal and paternal antigens.
- Class Loci Found on Presents antigen to
- Class I HLA-A, HLA-B, HLA-C All nucleated cells and platelets CD8+ cytotoxic T cells
Class II HLA-DR, HLA-DQ, HLA-DP Antigen-presenting cells (B cells, macrophages, dendritic cells) CD4+ helper T cells
Because siblings inherit one haplotype from each parent, two siblings have a 25% chance of being HLA-identical , a 50% chance of sharing one haplotype, and a 25% chance of sharing none. This is why related donors are sought for stem-cell transplants. HLA-DR matching is especially important for kidney graft survival.
Compatibility Testing
Three laboratory steps establish compatibility:
HLA typing of donor and recipient (now usually molecular/DNA-based, formerly serologic microcytotoxicity).
Antibody screening (PRA, panel-reactive antibody): measures the percentage of a panel to which the recipient has preformed HLA antibodies — a high PRA means a highly sensitized, hard-to-match recipient.
Crossmatch: recipient serum is tested against donor lymphocytes. A positive crossmatch (recipient antibody binds donor cells) is a contraindication to transplant because it predicts hyperacute rejection.
Sensitization to HLA antigens arises from prior pregnancy, transfusion, or transplantation .
Types Of Graft Rejection
The exam expects you to match each rejection type to its mechanism and timing.
Rejection Timing Mechanism
Hyperacute Minutes to hours Preformed recipient antibodies against donor HLA or ABO antigens; complement-mediated
- Acute Days to weeks T-cell-mediated (cellular) response against the graft; reversible with immunosuppression
- Chronic Months to years Antibody and cell-mediated injury → fibrosis and graft loss
A positive crossmatch predicts hyperacute rejection, which is why crossmatching is mandatory. Acute rejection is the target of most immunosuppressive therapy (e.g., calcineurin inhibitors such as cyclosporine and tacrolimus).
Graft-Versus-Host Disease (GVHD)
GVHD is the mirror image of rejection: instead of the host rejecting the graft, immunocompetent donor T cells attack an immunocompromised recipient's tissues (skin, gut, liver). It classically follows allogeneic bone marrow / hematopoietic stem-cell transplantation and can also follow transfusion of non-irradiated cellular blood products into an immunocompromised patient, or into an immunocompetent recipient who shares HLA with the donor, usually a relative.
Prevention in transfusion: gamma or X-ray irradiation of cellular blood components inactivates donor lymphocytes, preventing transfusion-associated GVHD. This is required for at-risk recipients (severe immunodeficiency, intrauterine and neonatal transfusions, hematopoietic transplant recipients, and directed donations from blood relatives).
ABO And Transplant
For solid-organ transplants, ABO compatibility generally follows the same rules as transfusion, because A and B antigens act as histocompatibility antigens on graft endothelium; an ABO-incompatible organ can trigger hyperacute rejection just as preformed HLA antibodies do.
High-Yield Traps
Class I (A, B, C) is on all nucleated cells and presents to CD8 cells; class II (DR, DQ, DP) is on antigen-presenting cells and presents to CD4 cells — do not reverse them.
A positive crossmatch contraindicates transplant (predicts hyperacute rejection).
Hyperacute = preformed antibody/minutes; acute = T cells/weeks — timing is the discriminator.
Irradiation , not leukoreduction, prevents transfusion-associated GVHD by inactivating donor lymphocytes.
HLA And Disease Association
Beyond transplantation, certain HLA alleles are statistically associated with autoimmune and other diseases, a relationship the exam may test. The strength of the link is expressed as a relative risk . Classic associations include HLA-B27 with ankylosing spondylitis and reactive arthritis, HLA-DR3/DR4 with type 1 diabetes, HLA-DR2 with multiple sclerosis and Goodpasture syndrome, and HLA-B*57:01 with abacavir hypersensitivity (now screened before prescribing the drug).
These are associations, not diagnostic tests — a patient can carry the allele without the disease — so the link guides risk assessment rather than confirming a diagnosis.
Platelet And Transfusion Immunology
HLA antigens also drive two transfusion problems. Platelet refractoriness occurs when a recipient develops HLA antibodies (from pregnancy, transfusion, or transplant) and fails to achieve the expected platelet count increment; the solution is HLA-matched or crossmatched platelets. Febrile non-hemolytic transfusion reactions are often caused by recipient antibodies against donor leukocyte (HLA) antigens or by accumulated cytokines, and are reduced by leukoreduction .
The Crossmatch Decision And Donor Selection
Matching a donor to a recipient combines several immunologic steps, and the exam frames them as a workflow:
- Step Purpose A bad result means
- ABO typing Confirm blood-group compatibility Incompatibility risks hyperacute rejection
- HLA typing Match class I and II antigens More mismatches lower graft survival
- PRA screen Quantify recipient sensitization High PRA = harder to find a compatible donor
- Crossmatch Detect recipient antibody to donor cells Positive crossmatch contraindicates transplant
Worked example: A highly transfused, multiparous renal candidate has a PRA of 95%. The high panel-reactive antibody means she is broadly sensitized and will react with most donors, so finding a negative crossmatch is difficult; transplanting across a positive crossmatch would precipitate hyperacute rejection. This integrates sensitization history, antibody screening, and crossmatch interpretation into a single decision — exactly the correlation reasoning the MLS exam rewards.
Additional Traps
HLA-disease links are associations (relative risk) , not diagnostic confirmation.
Platelet refractoriness from HLA antibodies is solved by HLA-matched platelets , not more random units.
A high PRA signals broad sensitization and predicts difficulty finding a compatible donor.